Podocytes are the key target for injury in proteinuric glomerular diseases that 25 result in podocyte loss, progressive focal segmental glomerular sclerosis (FSGS) and 26 renal failure. Current evidence suggests that the initiation of podocyte injury and 27 associated proteinuria can be separated from factors that drive and maintain these 28 pathogenic processes leading to FSGS. In nephrotic urine aberrant glomerular filtration 29 of Plasminogen (Plg) is activated to the biologically active serine protease Plasmin by 30 urokinase type plasminogen activator (uPA). In-vivo inhibition of uPA mitigates Plg 31 activation and development of FSGS in several proteinuric models of renal disease 32 including 5/6 nephrectomy. Here we show that Plasminogen (Plg) is markedly increased 33 in the urine in two murine models of proteinuric kidney disease associated with 34 podocyte injury: Tg26 HIV-associated nephropathy and the Cd2ap -/-
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model of FSGS. 35
We show that human podocytes express uPA and three Plg receptors: uPAR, tPA and 36 Plg-RKT. We demonstrate that Plg treatment of podocytes specifically upregulates 37 NADPH oxidase isoforms NOX2/NOX4 and increases production of mitochondrial-38 dependent superoxide anion (O 2 - ) that promotes endothelin-1 synthesis. 39
Plg via O 2 -also promotes expression of the B scavenger receptor CD36 and 40 subsequent increased intracellular cholesterol uptake resulting in podocyte apoptosis. 41
Taken together our findings suggest that following disruption of the glomerular filtration 42 barrier at the onset of proteinuric disease, podocytes are exposed to Plg resulting in 43 further injury mediated by oxidative stress. We suggest that chronic exposure to Plg 44 could serve as a "second hit" in glomerular disease and that Plg is potentially an 45 attractive target for therapeutic intervention. may contribute to tubule-interstitial disease and to glomerulosclerosis (11, 53) . 93
Clinically, most of the mechanisms linking proteinuria to CKD progression remain to be 94 fully defined (9, 13, 22, 54, 68) . Data from clinical and animal models have documented 95 significant quantities of biologically active urinary plasminogen (Plg) and the protease 96 plasmin in nephrotic range proteinuria of diverse etiologies (6, 81). Furthermore, in 97 patients in remission from nephrotic syndrome the urinary Plg/plasmin content is 98 minimal (1) thereby supporting the concept that under physiologic conditions podocytes 99 are not exposed to large concentrations of Plg; a fact further supported by its molecular 100 size (81 KD), which is larger than albumin (3). 101
It is well established that after binding onto cell surface receptors (42, 51, 52, 59 ) 102
Plg is protected from inhibitors, undergoes proteolytic activation and converts to the 103 serine protease plasmin. In many cell types plasmin initiates responses linked to both its 104 proteolytic as well as its non-proteolytic actions including cleavage of matrix proteins (62, 105 87), inactivation of VEGF (69), induction of reactive oxygen species (ROS) (85) as well 106 as activation of TGF β (23, 34, 43) . 107
Here we demonstrate that Plg is increased in the urine in two murine models of 108 proteinuric kidney disease associated with podocyte injury: the Tg26 HIV-associated 109 nephropathy mouse (37) and the Cd2ap -/-model of focal segmental glomerulosclerosis 110 (76). We show that immortalized human podocytes constitutively express and 111 synthesize uPA as well as the Plg receptors uPAR, tPA, and the novel trans-membrane 112 receptor Plg R-KT. 113
Our studies show, to our knowledge for the first time, that podocyte binding of Plg 114
upregulates NADPH oxidase isoforms NOX2 and NOX4 and elicits mitochondrial 115 production of superoxide anion (O 2 -) accompanied by: a) upregulation of the 116 multifunctional scavenger receptor CD36 (77, 96) resulting in increased podocyte 117 uptake of oxidized LDL (oxLDL) with subsequent apoptosis and b) induction of podocyte 118 synthesis of endothelin-1 a molecule that acts in a paracrine/autocrine fashion, and has 119 been implicated in podocyte-endothelial cell crosstalk and glomerular disease 120 progression (14, 35, 41, 61 
Mouse studies 141
Urine was collected from two proteinuric kidney disease models that have been well 142 characterized: 5week-old Cd2ap -/-mice (25, 72, 76, 90, 94) and 6week-old Tg26 mice (2, 4, 143 21, 32, 37, 38, 65) . Urinary Plg was measured using 2l urine with Elisa Kit (ICL E-144 90PMG) read at absorbance at 450 nm. Mouse creatinine was measured with an 145 enzymatic assay kit (Crystal Chem: #80350) . 146
147

Human Podocyte Culture 148
Human podocytes initially generated by MA Saleem Children's Renal Unit and 149
Academic Renal Unit, University of Bristol, UK (71) were generously provided by S. 150
Merscher-Gomez and A. Fornoni, University of Miami, who also provided initial 151 technical supervision of podocyte culture as reported (50, 64, 71) . Briefly, human 152 podocytes were cultured and differentiated in RPMI 1640 culture medium containing 153 10% FBS, 1% penicillin/streptomycin with or without 1% ITS, 50U/ml human interferon 154 as described (50, 71) . The immortalized normal human podocytes were propagated at 155 33°C and then thermoshifted for differentiation for 14 days at 37°C. Terminally 156 differentiated podocytes were starved in serum free RPMI 1640 medium for 24 hours 157 before the experiments were performed (24, 50, 64, 71) . O 2 -production was determined by using lucigenin enhanced chemiluminescence 163 as described in our previous publications (96). Human podocytes were treated with 164
Plg (1 μmol/L), the concentration of Plg found in human serum, (51, 52) for 6 hours as 165 determined in experiments of time responses to Plg up to 24 hrs (not shown). 166
To determine the source of ROS, the cells were pre-incubated with the following 167 compounds for 30 minutes before incubation with Plg: 1) NADPH oxidase inhibitors 168 diphenyleneiodonium (DPI, 1 μmol/L, Sigma-Aldrich) and APOCY (100 μmol/L, Sigma-169 Aldrich) (12, 39, 40, 96) , 2) AICAR, an agonist to AMP-activated protein kinase (100 170 μmol/L, Sigma-Aldrich) (19, 52, 86) , 3) EACA (0.2 mol/L, Sigma-Aldrich) (42, 52), and 4) 171
Amiloride (75 μM, Sigma-Aldrich) 172
173
Immunoblot analyses: 174
The cells were harvested with lysis buffer containing a cocktail of protein inhibitor 175 (Complete Mini, Roche Diagnostics GmbH, cat: 11836153001). Protein was quantified 176
by Bio-Rad assay, and 30 mg of total protein was first subjected to SDS-PAGE and then 177 transferred to nitrocellulose membranes. The membranes were incubated overnight in a 178 cold room with primary rabbit anti-CD36, anti-tPA, anti-WT1 and anti-uPAR (Santa Cruz 179 Biotechnology), anti-Phospho-AMPK, anti-AMPK, rabbit anti-NOX 4 (Santa Cruz 180 Biotechnology) and anti-NOX2 (AbCam) followed by incubation with a peroxidase-181 conjugated secondary antibody for 1 hour. All the Ab used equivalence-of-protein 182 loading and transfer was confirmed by re-blotting the samples with anti-β-actin antibody. 183
Immune reactive bands were detected by chemiluminescence and quantified by 184 
Statistics: 208
The results were expressed as mean ± SD. Statistical analyses were performed by 209 ANOVA with Bonferonni's correction for multiple comparisons, followed by Scheffe's test. 210
Significance was assumed at P< 0.05. 
Plasminogen receptor expression and superoxide upregulation in podocytes 243
In cultured human podocytes, we established the expression of uPA as well as 244 three well-characterized Plg receptors that are known to be blocked by the lysine 245 analogue EACA: uPAR, tPA and the novel receptor R-KT ( Figure 2A ) (42, 51, 52, 59) . 246
Previous studies in vivo and in vitro have demonstrated that several isoforms of NADPH 247 oxidase including NOX2, and NOX4 are present in podocytes and that ROS originating 248 from NADPH oxidase play an important role in ROS mediated podocyte injury. NOX4 is 249 the most abundant isoform in podocytes (10, 19, 31, 80) . RTPCR ( Figure 2B and 2C) 250 and western blotting (Figure 2D and 2E) showed that Plg significantly up-regulated 251 podocyte NOX4 and NOX2 expression. This was prevented by prior incubation with 252 EACA thereby demonstrating that Plg binding and activation was required (51, 85) . 253
Exposure of podocytes to Plg increased NADPH oxidase-mediated O 2 -production 254 ( Figure 3A ) that was prevented by the inhibitors of NADPH oxidase 255 diphenyleneiodonium (DPI), and by apocynin (APOCY) (39, 40) . 256
Plg concomitantly reduced the pAMPK/AMPK ratio ( Figure 3B ). AICAR, 5-257 aminoimidazole-4-carboxamide-1-riboside, is known to phosphorylate and activate 258 AMPK (18, 86). Pre-treatment of podocytes with AICAR prior to exposure to Plg 259 significantly prevented the reduction in pAMPK/AMPK ratio and concurrently inhibited 260 O 2 -production ( Figure 3A ). This suggests an important role of this stress-sensing kinase 261 in the biology of podocyte injury associated with oxidative stress (18, 86) . 262
263
Expression of the scavenger receptor CD36 is upregulated by Plasminogen 264
The B scavenger receptor CD36, which is present in many cells including 265 podocytes, (49) recognizes, binds and internalizes oxLDL (77, 96). Plg significantly 266 upregulated podocyte expression of CD36 ( Figure 4A ). This paralleled the increased 267 production of O 2 -induced by Plg ( Figure 3A ). The up-regulation of CD36 was prevented 268 by EACA as well as by the NADPH inhibitor APOCY and AICAR, the agonist of AMPK 269 (18, 19, 86) . Importantly, the significant inhibition of Plg up-regulation of CD36 by EACA, 270
APOCY and AICAR indicates the interdependence between Plg activation, increased 271
oxidative stress and CD36 up-regulation in podocytes. 272
Our group and others have shown that up-regulation of CD36 in human 273 macrophages increases uptake of oxLDL accompanied by increased synthesis of ROS 274 (77, 96). It is presently unknown whether upregulation of CD36 plays a similar role in 275 podocytes. Similar to macrophages, podocytes treated with oxLDL for 24 hrs showed a 276 significant increase in cholesterol accumulation ( Figure 4B ) (96), which was further 277 increased in podocytes treated with Plg plus oxLDL thereby suggesting that the 278 increased oxLDL uptake was linked to Plg upregulation of CD36 (77, 96). The off-target 279 effects of the diuretic amiloride as an inhibitor of uPA is well documented (30, 48, 88) . 280
We found that amiloride inhibited Plg induced upregulation of CD36 ( Figure 5A ) and 281
ROS superoxide generation (Figure 5B
). 282 283
Plasminogen enhances oxLDL-mediated podocyte apoptosis 284
Based on our novel findings that Plg up regulates CD36 ( Figure 4A ) and 285 increases oxLDL uptake ( Figure 4B Independent of the etiology, chronic severe non-selective proteinuria is a 305 harbinger of progression of chronic kidney disease (CKD) (24, 27, 67, 74, 79) . It has 306 long been suspected that the relentless trans-glomerular passage of selected plasma 307 macromolecules may contribute to podocyte injury as a "second hit". Studies have 308
shown that albuminuria itself may contribute to glomerular injury directly and indirectly 309 via podocytes uptake of fatty acids (FFA) bound to albumin (11) as well as by 310 sequestration of retinoic acid a molecule shown to be critical in protecting podocytes 311 from injury (44, 57). Data from both patients and experimental animals with nephrotic 312 syndrome have consistently shown their urine to contain large quantities of biologically 313 active Plg and the protease plasmin (1, 5, 6, (81) (82) (83) (84) 95) . 314
It has been demonstrated that plasmin in nephrotic urine proteolytically activates 315
ENaC, an effect that disappears during remission of the nephrotic syndrome (1, 5, 6, 316 81-84, 95) . In vitro and in vivo studies have demonstrated the ability of plasmin to 317 contribute to cellular injury and to inflammation via its proteolytic as well as its non-318 proteolytic actions (85). Interestingly previous studies in animals and in patients with 319 proteinuric nephropathies treated with EACA, the inhibitor of Plg activation to plasmin 320 (51, 52, 85), reported a marked reduction of proteinuria and glomerular injury (28). 321
We utilized two independent well-characterized models of progressive proteinuric 322 kidney disease, The Cd2ap -/-mouse model of FSGS and the Tg26 model of HIVAN. In 323 both, urinary Plg was significantly elevated (Figure 1 ). We have also used cultured 324 human podocytes (71) to further assist us in determining whether the Plg/plasmin 325 system could potentially participate as a "second hit" type of podocyte injury linked to 326
proteinuria. 327
In human podocytes we confirmed the expression of urokinase plasminogen 328 activator uPA that is synthesized by podocytes and of Plg receptors uPAR, tPA and Plg 329 R-KT (51, 52) ( Figure 2A ). uPAR has high-affinity for uPA, but has no intracellular 330 domain, which limits its signaling capacity. Plg R-KT co-localizes with uPAR and is a 331 unique trans-membrane protein that activates Plg because it exposes a C-terminal 332 lysine on the cell's surface (51, 52). In addition, Plg R-KT specifically interacts with tPA, 333 which secures Plg on the cell surface and promotes its activation to plasmin that once 334 bound to the cell surface is protected from its physiological inhibitors (51, 52, 85) . demonstrating that these effects are associated with Plg binding and activation ( Figure  340 2B-E). Next we determined that Apocynin, an inhibitor of NADPH oxidases, which are 341 considered to be the major source of ROS mediated podocyte injury (10, 31), prevented 342 the increase in O 2 -production induced by Plg ( Figure 3A) . 343 AMPK is a serine/threonine kinase that is present in podocytes and acts as an 344 energy sensor (7, 47). Once AMPK is phosphorylated (pAMPK) it becomes activated 345 and enables cells to reduce NADPH oxidase-dependent ROS formation (18, 19, 70, 86) . 346
We determined that exposure of podocytes to Plg reduced pAMPK ( Figure 3B ) and that 347 AICAR, an activator of AMPK (18, 19, 70) normalized pAMPK and concomitantly 348 inhibited Plg driven O 2 -production ( Figure 3A, 3B) . Of note AICAR has been shown to 349 have beneficial effects in diabetic nephropathy via similar mechanisms to those reported 350
here (18, 19, 86) . Hence AMPK may have a universal role in mitigating podocyte 351 pathobiology linked to oxidative stress (10, 18, 19, 70, 86) . experiments we determined that podocytes take up OxLDL and that incubation with Plg 379 had an additive effect that resulted in increased podocyte oxLDL uptake ( Figure 4B ) 380 accompanied by podocyte apoptosis (Figure 6 ). 381
The off target effect of Amiloride as an inhibitor of uPA was documented in early 382 studies reported in the cancer literature (66, 89) . In vivo experimental studies in Stroke 383
Prone SHR, Dahl salt sensitive and in 5/6 nephrectomy rats have shown that Amiloride 384 significantly reduces glomerular injury and proteinuria independent of blood pressure 385 (26, 33, 73) . In patients with type 2 diabetic nephropathy Amiloride lowered urine 386 plasminogen excretion and activation, and albumin/creatinine ratio (55). In the current 387 studies we determined that Amiloride inhibits Plg induced O 2 -production and CD36 388 upregulation in human podocytes ( Figure 5 ). This might explain, at least in part, the 389 mechanisms involved in the salutary effects of Amiloride in clinical and experimental 390 proteinuric renal disease. These studies also provide strong support to our hypotheses 391 regarding the potential role of Plg-plasmin in proteinuric renal diseases. 392 Elegant studies of biopsies from patients with FSGS presented evidence of 393 endothelial-mitochondrial oxidative stress associated with podocyte-endothelial cell 394 cross talk mediated by ET1 synthesized by podocytes (14, 15, 35, 41 ). Here we 395 demonstrated that Plg induced synthesis and release of ET1 was inhibited by pre-396 treatment of podocytes with either EACA or the NADPH inhibitor APOCY ( Figure 7B ) 397 (39, 40). Importantly, we made the new observation that selective inhibition of 398 mitochondrial ROS with Mito-Tempo was sufficient to completely prevent Plg induced 399 ET1 synthesis ( Figure 7B ) (14). 400
Crosstalk between mitochondria and NADPH oxidases is well documented and 401
likely represent a feed-forward vicious cycle of ROS production in which activation of 402
NADPH oxidases increase production of mitochondrial ROS and vice versa (16, 17). 403
In podocytes Nox 4 is predominately localized in mitochondria (19, 31) and has been 404 shown to produce hydrogen peroxide (H 2 O 2 ). Our results with apocyanin that inhibits 405 NOX2 and Mito Tempo would suggest (Fig 8) (16, 17) . 407
Overall our studies elucidated important new mechanisms that identified 408
apoptosis, linked to the interaction of Plg-CD36 -ox-LDL as a potential "second hit" in 409 podocyte injury and death associated with proteinuria ( Figure 8) (20, 36, 47, 54, 68, 91, 410 93) . Based on our studies we conclude that: 1) Plg activation on podocytes membranes 411 can play a significant role in a "second hit" type of podocyte injury associated with 412 chronic proteinuria independent of the initial etiology and 2) that oxidative stress 413 generated by Plg via NADPH oxidases plays a central role in these processes. 414
At the present time specific therapies for podocyte injury are not available. 
